ReviewFrontiers in bioscience (Landmark edition)2014
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.
Review in Frontiers in bioscience (Landmark edition), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05835739 (InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2), which is not on this map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 210 citations in OpenAlex.
- First-degree family history of prostate cancer is associated the risk of breast cancer and ovarian cancer.Medicine · 2021Pooled it
- Integrative Genomic and Transcriptomic Insights into High-Altitude Adaptation in Changthangi Goats.Applied biochemistry and biotechnology · 2026Article
- From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management a systematic review.Biochemistry and biophysics reports · 2026Review
- Effect of the hsa-microRNA 200c-3p/ZEB1 loop in epithelial-mesenchymal transition of ovarian cancer cells.Oncology letters · 2026Article
- Breast cancer susceptibility gene 2 upregulation alleviated cardiac hypertrophy in angiotensin II-treated mice.Biochemistry and biophysics reports · 2026Article
- Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements.iScience · 2026Review
- Homologous recombination pathway alterations in basal-like breast cancer.Frontiers in oncology · 2026Review
- Metachronous triple primary malignancies: a case report of NGS-guided multidisciplinary management and literature review.Frontiers in oncology · 2026Review
- Optimizing endocrine adjuvant therapy in HR+/HER2- breast cancer: supplemental strategies and innovations.Annals of medicine and surgery (2012) · 2025Review
- Identification and mechanism analysis of biomarkers related to butyrate metabolism in COVID-19 patients.Annals of medicine · 2025Article
- Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer.JNCI cancer spectrum · 2025Article
- Storage Time and DNA Quality DetermineCancers · 2025Article
- Article
- Mammalian Species-Specific Resistance to Mammary Cancer.Journal of mammary gland biology and neoplasia · 2025Review
- Outcome-guided Bayesian clustering for disease subtype discovery using high-dimensional transcriptomic data.Journal of applied statistics · 2025Article
- Case report: Deciphering the clinical significance of a novel partialFrontiers in oncology · 2025Article
- Review
- Research Progress on the Relationship Between Artificial Sweeteners and Breast Cancer.Biomedicines · 2024Review
- Enhanced cancer cell proliferation and aggressive phenotype counterbalance in breast cancer with high BRCA1 gene expression.Breast cancer research and treatment · 2024Article
- BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.Breast cancer research and treatment · 2024Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The Breast Cancer Susceptibility Genes, BRCA1 and BRCA2, are the dynamic regulators of genomic integrity. Inherited mutations in these genes are associated with the development of cancer in multiple organs including the breast and ovary. Mutations of BRCA1/2 genes greatly increase lifetime risk to develop breast and ovarian cancer and these mutations are frequently observed in hereditary breast and ovarian cancers. In addition, misregulation and altered expressions of BRCA1/2 proteins potentiate sporadic forms of breast cancer. In particular, both genes contribute to DNA repair and transcriptional regulation in response to DNA damage. Thus, deficiencies of BRCA1/2 functions lead to the accumulation of genetic alterations and ultimately influence the development of cancer. Studies since identification of both BRCA1 and BRCA2 have provided strong evidences for their tumor suppressor activities specifically for breast and ovarian cancer and this article aims to review the current state of knowledge regarding the BRCAs and associated cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.